News & Videos - BIOSENIC - English

PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis....

PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger. Details of the notifications can be found below and the full versions of the transparency...

PRESS RELEASE - PRIVILEGED INFORMATION A final circular of the creditors on the basis of XX 83/23 of the Economic Law Code (ELC) will take place before the Court grants authorisation, in accordance with article XX 83/26 of the ELC, to submit the plan to the vote of each class of creditors and to homologation. The creditors will be aware of the plan, which by law contains information that could be privileged. Mont-Saint-Guibert, Belgium, 11 April 2024, 14:00 CET – BioSenic (Euronext Brussels...

PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of...

PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international patent to support the newly focused indication of JTA-004. Mont-Saint-Guibert, Belgium, January 23, 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company focused on serious autoimmune and inflammatory diseases and cell therapy, today announces the filing of a U.S....

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...

REGULATED INFORMATION Following the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, allowing to start its phase 3 international clinical trial with oral arsenic trioxide (ATO) in the first-line treatment of chronic Graft-versus-Host-Disease (cGvHD). Mont-Saint-Guibert, Belgium, October 25, 2023, 7.00 am CEST – BioSenic provides third quarter 2023 Business Update Following the...

INSIDE INFORMATION Mont-Saint-Guibert, Belgium, October 18, 2023, 7.00am CEST – BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024 Mont-Saint-Guibert, Belgium, October 18, 2023, 7.00am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has reached a definitive agreement...

REGULATED INFORMATION This is a corrected version of the original PR "Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS" published on October 17, 2023, 7am CEST. There are two typographical corrections, one in the headline and one in the first paragraph where 2022 was written instead of 2023. Correction: Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS Article...

REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 17, 2022, 7am CEST – Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 17, 2022, 7am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...

Information on the total number of voting rights and shares Mont-Saint-Guibert, Belgium, September 1, 202 3 , 7 . 00 a m CE S T – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds. The following information...

INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration Enriched IP portfolio protects ATO with demonstrated therapeutic potential for indications ranging from cancer to immune or infectious diseases Mont-Saint-Guibert, Belgium, 24 August, 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell...

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, August 2 , 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds. The following information is published in accordance with article 15 of...

INSIDE INFORMATION Agreement with the main creditors of BioSenic for a standstill running until October 2023 Mont-Saint-Guibert, Belgium, July 10 th , 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and organ/function repair, today announces a further update on its financial arrangements with its main historical creditors, Patronale, Monument and the European Investment Bank....

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June 1 st , 202 3 , 7 . 00 a m CE S T – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs). The following information is published in accordance with...

INSIDE INFORMATION BioSenic plans to further develop its program on an active injectable viscosupplement JTA, combi ni ng anti-pain and anti-inflammatory characteristics on a subtype of knee osteoarthritis. Mont-Saint-Guibert, Belgium, May 17 th , 202 3 7 . 00am CET – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces an update to its future plans for clinical development of...

INSIDE INFORMATION International patent to allow the development of an industrial biomarker analysis kit which could generate a turnover of 30 to 40 million euros globally Mont-Saint-Guibert, Belgium, May 4 th 202 3 , 7 . 00am CET – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the submission of a key patent in the use of its ATO platform. The patent, entitled Diagnostic...

REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in Q2 2023 ATO Phase III to be launched in 2023 Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, April 27 , 2023, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update and full year financial results for the year ending 31 December 2022, prepared in accordance...

INSIDE INFORMATION P atent cover s t he therapeutic use of a new composite formulation of anti -inflammatory compounds with unique advantages BioSenic’s new formulation lowe rs the dosage of arsenic trioxide by combining it with copper salts to maintain therapeutic efficacy, with the potential of administ ration through multiple routes, including intravenous, oral and other novel routes of administration Mont-Saint-Guibert, Belgium, April 18 , 202 3 , 7 . 00 am CET – BioSenic (Euronext...

INSIDE INFORMATION Appointment to drive late-stage clinical development of BioSenic’s cell therapy and autoimmune disease platforms Mont-Saint-Guibert, Belgium, April 3, 202 3 , 7 .30 am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces it has appointed Lieven Huysse, MD, as permanent Chief Medical Officer (CMO), effective 17 April 2023. Lieven Huysse will succeed Michel Wurm’s, MD,...